Meeting
2023 ASCO Annual Meeting
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
Authors
Patricia LoRusso
Yale University School of Medicine, Yale Cancer Center, New Haven, CT
Patricia LoRusso , Mrinal M. Gounder , Noboru Yamamoto , Manish R. Patel , Todd Michael Bauer , Junxian Geng , Reinhard Sailer , Yuefen Tang , Girish Jayadeva , Patrick Schöffski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03449381
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11554)
DOI
10.1200/JCO.2023.41.16_suppl.11554
Abstract #
11554
Poster Bd #
488
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.
First Author: Alexander Peltzer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
First Author: Noboru Yamamoto
Poster
2019 ASCO Annual Meeting
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
First Author: Curtis Robert Chong
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli